Incanthera Plc
AAQSE:INC3.50
GBX
0.00
(0.00%)
ISIN
GB00BGL7YW15
Return %
Stock
S&P 500
1Y
0.00
14.20
3Y
-43.55
81.12
5Y
-71.77
68.34
Capital Structure
GBP
•
in mil. unless spec.Working Capital
GBP
•
in mil. unless spec.Growth Rates
GBP
•
in mil. unless spec.Semi-annual Revenue
GBP
•
in mil. unless spec.Semi-annual Earnings Per Share
GBP
•
in mil. unless spec.Semi-annual Dividends Per Share
GBP
•
in mil. unless spec.Company Description
- CEO
- Stuart Robertson
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Manchester United Kingdom
- Website
- incanthera.com
- Similar Companies
- Business
- Incanthera plc is a United Kingdom-based dermatology and pharmaceutical company engaged in the development and commercialisation of proprietary transdermal delivery technologies, dermatological products, and advanced skincare formulations. Founded in 2010 and headquartered in Manchester, United Kingdom, the company operates across the biotechnology, healthcare, and cosmeceutical sectors, focusing on innovative topical delivery technologies that transport active ingredients directly across the dermal barrier for targeted cellular and therapeutic applications. Incanthera structures its core offerings across three primary product and technology segments: Skin+CELL, an advanced luxury anti-ageing and cosmeceutical skincare line utilising cellular energy delivery complexes; proprietary transdermal formulation technologies designed to enhance the permeation and bioavailability of active compounds; and a heritage pipeline of dermatology and oncology therapeutics, including targeted prodrugs and preventative formulations for skin conditions such as solar keratosis. The company targets consumer skincare markets, dermatological healthcare channels, and specialty cosmetics retailers across the United Kingdom, continental Europe, and Asia. In recent operational and strategic developments, Incanthera transitioned from a research-and-development enterprise into a revenue-generating commercial business following a major commercial partnership and distribution agreement with Marionnaud, a luxury perfumery and cosmetics retail subsidiary of A.S. Watson Group. Under this agreement, Marionnaud manages the commercial retail launch and distribution of the Skin+CELL range across key European markets, including Switzerland and Austria, supported by significant initial and recurring manufacturing purchase orders, commercial inventory financing, and strategic plans for broader multi-territory expansion across European and Asian retail networks.